CHK1i+LDHU triggered a strong anti-tumour T cell response demonstrated by the very high proportion of tumour antigen reactive CD4+ and CD8+ T cells in the blood (and spleen; data not shown) of treated mice. Here, CD8A is linked to neoplasm.